Evidence map›Paper›PMID 40788398›Full record

ArticleArchives of microbiology2025

Bactericidal activity of gallic acid against multidrug-resistant Mycobacterium tuberculosis.

Min Wei, Amirabas Bostani, Nadi Jamalsi, Hasan Baqin, Peng Wen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bioactive spectrum of goji berries (Food chemistry: X · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Min WeiDepartment of Respiratory and Critical Care Medicine, Shandong Public Health Clinical Center, Shandong University, Shandong, 250013, China.
Amirabas BostaniMedical Laboratory Department, Amir A'lam Hospital, Tehran, Iran.
Nadi JamalsiMedical Laboratory Department, Amir A'lam Hospital, Tehran, Iran.
Hasan BaqinMedical Laboratory Department, Amir A'lam Hospital, Tehran, Iran.
Peng WenDepartment of Respiratory and Critical Care Medicine, Shandong Public Health Clinical Center, Shandong University, Shandong, 250013, China. wp1980jn@sina.com.ORCID http://orcid.org/0009-0008-0321-7201

Funding

Development Plan of Medicine and Health Science and Technology of Shandong Province 202303021558
6 · The paper itself

Abstract

The persistent rise of multidrug-resistant (MDR) bacteria represents a significant public health challenge, necessitating the exploration of alternative therapeutic options. The slow pace of approval for new anti-tuberculosis (TB) medications underscores the urgent need to identify potential alternative agents. Gallic acid (GA) possesses numerous biological properties, including antibacterial and antiseptic effects. In this study, both standard and MDR strains of M. tuberculosis were utilized to assess the antibacterial efficacy of GA and related mechanisms. GA achieved minimum inhibitory and minimum bactericidal concentrations comparable to those of the examined antibiotics with significantly lower cytotoxicity in the THLE-3 cell line (p-value < 0.05). Furthermore, GA displayed bactericidal properties, enhanced the effectiveness of moxifloxacin and levofloxacin against MDR M. tuberculosis, and modulated the expression of efflux pump genes, specifically Rv1410c and Rv1258c (p-value < 0.001). These results contribute to a deeper understanding of GA's antibacterial potential and suggest a novel alternative approach for managing MDR bacterial infections.

Indexed as

Antitubercular AgentsGallic AcidMycobacterium tuberculosisTuberculosis, Multidrug-ResistantBacterial ProteinsCell LineDrug Resistance, Multiple, BacterialHumansLevofloxacinMicrobial Sensitivity TestsMoxifloxacinAntitubercular AgentsBacterial ProteinsGallic AcidLevofloxacinMoxifloxacinAntibioticDrug-resistantEffluxFlavonoidGallic acidMycobacteriaTuberculosis

Identifiers

PMID40788398
PMCPMC12339633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.